Abstract: Methods for electrical modulation of inflammation or serum TNF levels in a subject.

Abstract: Methods for electrical modulation of inflammation or serum TNF levels in a subject.

Abstract: Methods are disclosed for treating a subject having a disease or disorder comprising stimulating a nerve of the subject with a corrective stimulus pattern derived from a disease-specific, condition-specific, endogenous mediator-specific or pharmacologic agent-specific neurogram in an amount and manner effective to treat the disease or disorder.

Abstract: Methods are disclosed for treating a subject having a disease or disorder comprising stimulating a nerve of the subject with a corrective stimulus pattern derived from a disease-specific, condition-specific, endogenous mediator-specific or pharmacologic agent-specific neurogram in an amount and manner effective to treat the disease or disorder.

Abstract: Methods are disclosed for treating a subject having a disease or disorder comprising providing the subject with an acoustic energy stimulus derived from a disease-specific, condition-specific, endogenous mediator-specific or pharmacologic agent-specific neurogram in an amount and manner effective to treat the disease or disorder.

Abstract: Compositions and methods are provided comprising choline acetyltransferase (ChAT) and PEGylated ChAT for treating hypertension.

Abstract: Methods are disclosed for treating a subject with metabolic syndrome, fatty liver disease, insulin resistance, inflammation or elevated body weight using hepatic ultrasound.

Abstract: Methods for electrical modulation of inflammation or serum TNF levels in a subject.

Abstract: Methods for electrical modulation of inflammation or serum TNF levels in a subject.

Abstract: Methods are disclosed for preventing systemic infection or controlling metastases or providing a vaccine adjuvant in a subject, the methods comprising stimulating one or more peripheral nerves innervating one or more lymph nodes of the subject.

Abstract: Methods are disclosed for treating a subject having a disease or disorder comprising stimulating a nerve of the subject with a corrective stimulus pattern derived from a disease-specific, condition-specific, endogenous mediator-specific or pharmacologic agent-specific neurogram in an amount and manner effective to treat the disease or disorder.

Abstract: The subject matter of the present disclosure generally relates to techniques for neuromodulation of tissue that include applying energy (e.g., electromagnetic energy) into the target tissue to cause altered activity of a neuron in the tissue. In certain embodiments, the altered activity causes a change in one or molecules in the tissue or blood.

Abstract: Methods are disclosed for treating a subject having a disease or disorder comprising stimulating a nerve of the subject with a corrective stimulus pattern derived from a disease-specific, condition-specific, endogenous mediator-specific or pharmacologic agent-specific neurogram in an amount and manner effective to treat the disease or disorder.

Abstract: Methods are disclosed for treating inflammation and sepsis and for promoting thermoregulation by activating neurons expressing TRPA1 in the vagus nerve.

Abstract: Methods for electrical modulation of inflammation or serum TNF levels in a subject.

Abstract: Methods are disclosed for preventing systemic infection or controlling metastases or providing a vaccine adjuvant in a subject, the methods comprising stimulating one or more peripheral nerves innervating one or more lymph nodes of the subject.

Abstract: Methods are disclosed for treating a subject having a disease or disorder comprising providing the subject with an acoustic energy stimulus derived from a disease-specific, condition-specific, endogenous mediator-specific or pharmacologic agent-specific neurogram in an amount and manner effective to treat the disease or disorder.

Abstract: Methods are disclosed for treating a subject having a disease or disorder comprising stimulating a nerve of the subject with a corrective stimulus pattern derived from a disease-specific, condition-specific, endogenous mediator-specific or pharmacologic agent-specific neurogram in an amount and manner effective to treat the disease or disorder.

Abstract: The invention is directed to an isolated genomic polynucleotide sequence encoding interleukin-four induced protein as well as methods for obtaining said protein by expressing said polynucleotide sequences. The invention is also directed to constructs, vectors and hosts comprising such sequences, and oligonucleotide probes which hybridize to said polynucleotide sequences and kits comprising said probes. Additionally, the invention is directed to compositions comprising said polynucleotides and methods for using said compositions to treat, prevent or ameliorate pathological disorders, e.g., immune related disorders and novel methods of using the interleukin-four induced protein. The invention is also directed to methods for obtaining an antibody that binds to an epitope on said protein. The invention is further directed to a method for measuring the activity of said protein by measuring its L-amino acid oxidase activity.